People with type 2 diabetes are at high risk for diabetic nephropathy. Researchers recently investigated the effects of somalutide on kidney function in type II diabetic patients.
This post hoc analysis of the SUPPINE1-5, SUPPINE6, and SUPPINE7 scientific study involved 8416 patients with type 2 diabetes who received weekly intradermal injections of 0.5mg and 1.0Mg of somallutide or control (both active treatment and placebo-effect groups). The ultimate goal of scientific research is the effect of treatment on renal tubular filtration rate (eGFR), urinary albumin-to-creatinine ratio (UACR) and renal function.

In SUPPINE1-5 and SUPPINE7 scientific studies, continuous injection of somallutide resulted in significant improvement in renal tubular filtration rate after 12 weeks, with an eGFR estimated treatment difference (ETDs) of -2.15mL/minper1.73m2 in the 0.5mg group compared with placebo. The ETDs in the 1.0Mg somallutide group was -3.00mL/minper1.73m2.
In SUPPINE1-5 and SUPPINE7 scientific studies, through the completion of scientific study, the ETDs, as compared with placebo effects, were − 1.58mL per minute per1.73m2 in the 0.5-mg group and − 2.02mL per minute per1.73m2 in the 1.0-mg group. In SUSTAIN6, at 16 weeks, ETDs were -1.29mL/minper1.73m2 for the 0.5mg group and -1.56mL/minper1.73m2 for the 1.0Mg group, compared with placebo effect, but between weeks 16 and 104, ETDs were -1.56 ml /minper1.73m2 for the 1.0 mg group. The effect of somallutide on eGFR was reduced.

However, overall, the effect of somallutide on eGFR was not evident in SUSTAIN6. In SUPPINE1-5, by the end of the experiment, the UACR was 0.917 for 0.5mg of somallutide, 0.836 for 1.0Mg of somallutide, and 1.239 for placebo. Somallutide had substantial efficacy in reducing UACR (estimated cure rates of 0.74 and 0.68 in the 0.5-mg and 1.0-mg groups, respectively). In the SUSTAIN6 Science study, by week 104, the UACR was 0.973 in the 0.5-mg group, 0.858 in the 1.0-mg group, and 1.302 in the placebo effect group. The efficacy of somallutide in reducing UACR was notable (estimated cure rates of 0.5-mg and 1.0-mg somallutide, 0.75 and 0.66, respectively).

"In the SUSTAIN1-7 scientific study, eGFR decreased first in patients with normal renal function who received somallutide, but overall, there was no significant difference in the effect of somallutide compared with placebo." "In the SUSTAIN1-6 scientific study, injection of somallutide reduced UACR in patients with preexisting microalbuminuria or albuminuria, but had no effect in those with normal albuminuria." There was no significant difference in renal adverse reactions between the groups.
"In patients with type II diabetes, treatment with somallutide has no significant effect on the renal tubular filtration rate, but it can significantly reduce the urinary albumin-to-creatinine ratio without increasing the risk of adverse effects on renal function."